Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

PBD Biotech appoints new Commercial Director to drive expansion

PBD Biotech is delighted to announce the appointment of Mark Hammond as its new Commercial Director.
  • November 1, 2018
  • Company, People
  • staff
Mark Hammond, PBD Biotech CEO

With a strong track record in the pharmaceutical and healthcare sectors, Mark brings with him a wealth of business development and commercial expertise to lead the diagnostic developer’s international growth strategy.

Commenting on his appointment, Mark said, “I am delighted to take up this role with PBD Biotech, an early-stage company that is fast gaining international traction.

“There is an enormous need for tools to better detect and control TB and other mycobacterial disease in livestock and other animals.

“PBD’s Actiphage® test is unique in that it can rapidly identify the presence of live bacteria within hours and has huge global potential as a fast and accurate diagnostic. I am excited about what the future holds for PBD Biotech.”

Prior to joining Suffolk-based PBD Biotech, Mark held a number of senior leadership roles covering strategic, commercial and operational development within both public and private companies such as Aesica Pharmaceuticals, Intertek and Melbourn Scientific.

PBD Biotech has recently closed a successful strategic funding round that has accelerated the company’s global commercialisation strategy. Its Actiphage products include a blood test, to aid early detection of disease and improve its management in herds, and a milk test for quality assurance of dairy products.

PBD Biotech CEO, Dr Berwyn Clarke, said, “Mark’s knowledge of pharma and healthcare will be invaluable to PBD Biotech as we build on the company’s fast-growing reputation as a leader in mycobacterial diagnostics. The ability of the company to attract someone of Mark’s capability is a real endorsement of the growing recognition of our technology as a transformational tool in disease management in both animals and in man.”

He continued, “Actiphage’s phage-based detection method has applications across a number of market sectors and geographies. Mark will be integral to realising its full commercial potential.”

With having secured its key patent from the European Patent Office, Mark’s first focus will be securing the significant market interest that has been developed from multiple sectors within the UK and internationally – with major initiatives already underway in France, Canada, the USA and South America.

Share:

Related posts

Loading...
Marie Roskrow

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

January 17, 2023
Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need, PBD Biotech is announcing that it has appointed Dr Marie Roskrow to chair its board and has expanded its scientific...
Marie Roskrow

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

January 17, 2023
Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need,...
Tom Kellner

PBD Biotech expands its North American operations

January 27, 2022
PBD Biotech is expanding its North American team. Tuberculosis (TB) and Johne’s Disease expert Tom Kellner has been appointed as Director of Operations in North America, to advise on regulatory affairs and provide technical and customer support.
Tom Kellner

PBD Biotech expands its North American operations

January 27, 2022
PBD Biotech is expanding its North American team. Tuberculosis (TB) and Johne’s Disease expert Tom Kellner has been appointed as...
Tom Green

PBD Biotech appoints Tom Green as new Board Chairman

September 18, 2017
UK-based biotech PBD Biotech is delighted to announce the appointment of Mr Tom Green as chairman of its Board.
Tom Green

PBD Biotech appoints Tom Green as new Board Chairman

September 18, 2017
UK-based biotech PBD Biotech is delighted to announce the appointment of Mr Tom Green as chairman of its Board.

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More